The deal between Biocon and Pfizer to market a range of insulin products may be in crisis. Vikas Dandekar, the India Bureau Chief of PharmAsia News who broke this story tells CNBC-TV18 that while sources are saying talks are on to salvage the deal, it is most likely to be called off.
first published: Mar 12, 2012 09:59 pm
A collection of the most-viewed Moneycontrol videos.
Live: Nifty reclaims 25,300, registers over 1% gain this week | Closing Bell
Live: Will Nifty bulls aim to break 25,250 after strong TCS Q2? | Opening Bell
TCS Q2 Earnings Live: Margin, Revenue Beat Street Estimates
Live: Nifty reclaims 25,100 ahead of TCS Q2 results; pharma, metals shine | Closing Bell
